Generic Name and Formulations:
Bimatoprost 0.01%, 0.03%; oph soln; contains benzalkonium chloride.
Indications for LUMIGAN:
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
≥16yrs: 1 drop once daily in the PM.
<16yrs: not recommended.
Do not exceed recommended dose. Renal or hepatic impairment. Ocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.
Allow at least 5 minutes between application of other topical ophthalmic agents.
Conjunctival hyperemia, eyelash growth, ocular itching or dryness, visual disturbances, foreign body sensation, other local effects, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, blepharitis, cataract, keratitis, photophobia, infection, headache, abnormal liver function tests, asthenia, hirsutism.
Soln—2.5mL, 5mL, 7.5mL
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness